Immune Response - Topnews!?!? - 500 Beiträge pro Seite
eröffnet am 23.02.00 13:34:23 von
neuester Beitrag 31.03.00 16:14:53 von
neuester Beitrag 31.03.00 16:14:53 von
Beiträge: 18
ID: 68.929
ID: 68.929
Aufrufe heute: 0
Gesamt: 1.480
Gesamt: 1.480
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 17 Minuten | 7173 | |
| vor 17 Minuten | 5947 | |
| heute 11:51 | 4560 | |
| 11.01.09, 16:18 | 4314 | |
| vor 25 Minuten | 4096 | |
| vor 51 Minuten | 3563 | |
| vor 19 Minuten | 2450 | |
| vor 1 Stunde | 2123 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 4. | 8,2010 | +69,49 | 162 | |||
| 2. | 1. | 18.711,86 | -0,09 | 157 | |||
| 3. | 7. | 44,10 | +55,94 | 118 | |||
| 4. | 9. | 7,0060 | +0,43 | 55 | |||
| 5. | 6. | 12,770 | +5,12 | 54 | |||
| 6. | 3. | 162,96 | +2,27 | 52 | |||
| 7. | 5. | 0,1930 | -1,53 | 49 | |||
| 8. | 10. | 0,4320 | +18,68 | 45 |
Feedback
top news auf www.yahho.com/r/sq
bid/ask 19/20
bid/ask 19/20
erfolgreiche HIV Tests in Thailand ,News von heute 7:00
Hey e.broker,
der Link funktioniert nicht, kannst Du die News nicht hier ins Board stellen.
Danke
Loriot
der Link funktioniert nicht, kannst Du die News nicht hier ins Board stellen.
Danke
Loriot
shit, morgen kann/werde ich etwa 7 % meines depots steuerfrei verkaufen, die für immune response vorgesehen waren. nun diese meldung und ein vorbörslicher kurs von 20 $:
The Immune Response Corporation Announces Results From A Phase II Clinical Trial of REMUNE in Thailand at The WHO-UNAIDS Vaccine Advisory Committee Meeting
CARLSBAD, Calif., Feb. 23 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that the results from a double blind placebo controlled trial of REMUNE(TM) alone versus adjuvant alone in 297 Thai HIV-1 infected subjects were presented to the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) vaccine advisory committee meeting in Geneva Switzerland on February 23, 2000. The results presented revealed a significant effect (P<0.05) of REMUNE on the primary endpoint of CD4 cells. The results of the 40 week trial also showed a significant effect (P<0.05) on HIV specific immune function favoring the REMUNE treated group. Trinity Medical Group, the Company`s corporate partner for development of REMUNE in Southeast Asia, has informed the Company that the results of the trial have been submitted to the Thai Ministry of Public Health.
Data was submitted to the Thai Ministry of Public Health from a 40-week trial of 297 asymptomatic, HIV-infected Thai patients not taking antiviral drug therapy. Patients were randomized to receive either REMUNE or adjuvant (a general immune stimulant) as a control at 0, 12, 24, and 36 weeks. The primary endpoint for the trial was a change in CD4 helper T-cell counts (immune cells selectively destroyed by HIV). CD4 cell counts and viral load are currently the only two accepted, validated clinical markers for HIV infection. Better clinical outcomes have been associated with increases in CD4 cell counts and decreases in viral load.
The results suggested that there was a significant increase (P<0.05) in CD4 cell counts in the REMUNE treated group compared to the control group. In addition, both humoral (P<0.05) and cell-mediated (P<0.05) immune responses specifically against HIV were elevated in patients treated with REMUNE compared to controls. On average, REMUNE treated subjects increased their T cell counts by 84 cells from baseline. Typically, CD4 cells decrease over time in patients not taking antiviral drugs.
Both treatment groups remained stable in viral load during the blinded period of the 40 week trial. Additional data on 68 of the subjects who continued to receive REMUNE alone revealed that 87% (59/68) remained stable or decreased in viral load by week 88. Of those that decreased in viral load, the average decrease was 0.99 log. Typically, viral load increases over time in subjects not taking antiviral drugs.
Cell-mediated immune responses were assessed by a skin test called HIV-delayed type hypersensitivity (DTH). In this test, skin reactions are measured in response to immunization with HIV antigens (proteins that elicit an immune response). A positive reaction is caused primarily by CD4 helper T cells specific for HIV. These CD4 helper T cells proliferate and secrete factors called cytokines that attract other immune cells to the immunized area. A positive reaction indicates the presence of sensitized T cells specific for HIV, which means that an HIV-specific immune response is occurring after treatment with REMUNE.
"It is estimated that 1.4 million people may be infected with HIV by the end of 2000 in Thailand. These patients are in urgent need of effective treatment alternatives, and we are encouraged by the apparent improvement in immune health observed in patients treated with REMUNE," said Dr. Vina Churdboonchart at Mahidol University, Bangkok, Thailand, principal investigator of the Phase II clinical trial in Thailand. "As the UN has recently noted, the AIDS epidemic in developing countries where access to antiviral drugs is limited is now having a global impact, and based on these results, REMUNE may represent a rational treatment option for us."
The Immune Response Corporation Announces Results From A Phase II Clinical Trial of REMUNE in Thailand at The WHO-UNAIDS Vaccine Advisory Committee Meeting
CARLSBAD, Calif., Feb. 23 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that the results from a double blind placebo controlled trial of REMUNE(TM) alone versus adjuvant alone in 297 Thai HIV-1 infected subjects were presented to the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) vaccine advisory committee meeting in Geneva Switzerland on February 23, 2000. The results presented revealed a significant effect (P<0.05) of REMUNE on the primary endpoint of CD4 cells. The results of the 40 week trial also showed a significant effect (P<0.05) on HIV specific immune function favoring the REMUNE treated group. Trinity Medical Group, the Company`s corporate partner for development of REMUNE in Southeast Asia, has informed the Company that the results of the trial have been submitted to the Thai Ministry of Public Health.
Data was submitted to the Thai Ministry of Public Health from a 40-week trial of 297 asymptomatic, HIV-infected Thai patients not taking antiviral drug therapy. Patients were randomized to receive either REMUNE or adjuvant (a general immune stimulant) as a control at 0, 12, 24, and 36 weeks. The primary endpoint for the trial was a change in CD4 helper T-cell counts (immune cells selectively destroyed by HIV). CD4 cell counts and viral load are currently the only two accepted, validated clinical markers for HIV infection. Better clinical outcomes have been associated with increases in CD4 cell counts and decreases in viral load.
The results suggested that there was a significant increase (P<0.05) in CD4 cell counts in the REMUNE treated group compared to the control group. In addition, both humoral (P<0.05) and cell-mediated (P<0.05) immune responses specifically against HIV were elevated in patients treated with REMUNE compared to controls. On average, REMUNE treated subjects increased their T cell counts by 84 cells from baseline. Typically, CD4 cells decrease over time in patients not taking antiviral drugs.
Both treatment groups remained stable in viral load during the blinded period of the 40 week trial. Additional data on 68 of the subjects who continued to receive REMUNE alone revealed that 87% (59/68) remained stable or decreased in viral load by week 88. Of those that decreased in viral load, the average decrease was 0.99 log. Typically, viral load increases over time in subjects not taking antiviral drugs.
Cell-mediated immune responses were assessed by a skin test called HIV-delayed type hypersensitivity (DTH). In this test, skin reactions are measured in response to immunization with HIV antigens (proteins that elicit an immune response). A positive reaction is caused primarily by CD4 helper T cells specific for HIV. These CD4 helper T cells proliferate and secrete factors called cytokines that attract other immune cells to the immunized area. A positive reaction indicates the presence of sensitized T cells specific for HIV, which means that an HIV-specific immune response is occurring after treatment with REMUNE.
"It is estimated that 1.4 million people may be infected with HIV by the end of 2000 in Thailand. These patients are in urgent need of effective treatment alternatives, and we are encouraged by the apparent improvement in immune health observed in patients treated with REMUNE," said Dr. Vina Churdboonchart at Mahidol University, Bangkok, Thailand, principal investigator of the Phase II clinical trial in Thailand. "As the UN has recently noted, the AIDS epidemic in developing countries where access to antiviral drugs is limited is now having a global impact, and based on these results, REMUNE may represent a rational treatment option for us."
Trading Spotlight
http://www.yahoo.com/r/sq
imnr eingeben
imnr eingeben
vorbörslich usa 20 1/4
kostenlose realtime unter http://bluejack.debox.de
kostenlose realtime unter http://bluejack.debox.de
hallo
vorbörslich 20 1/4
sorry, hatte probleme beim posten!
Nun ja, zumindestens heute scheint IMNR nicht auf die Meldung anspringen zu wollen. Unter Yahoo kann man einen Artikel abrufen, der erklärt warum: vielleicht ist die Methode nicht für die USA anwendbar,da dort die Wirksamkeit eines solchen Medikaments nach speziellen Kriterien gemessen wird. Dies könnte die verhaltene Reaktion auf die tolle Meldung erklären. Außerdem ist die Aktie ja zuletzt sehr gut gelaufen. Warten wir einfach mal ab. Ich habe heute auch noch einmal nachgekauft und bin optimistisch.
Was meint Ihr ,wars das erstmal für IMNR oder sollte man nachkaufen??
Bin seit 10 Euro dabei,was soll ich tun.
Was meint Ihr?????
Bitte um Antwort Euer Talker
Bin seit 10 Euro dabei,was soll ich tun.
Was meint Ihr?????
Bitte um Antwort Euer Talker
Wäre dankbar für Erklärung des folgenden!!Von Yahoo.com
Wednesday February 23, 2:45 pm Eastern Time
U.S. Options - Immune Response volume increases
CHICAGO, Feb 23 (Reuters) - Options volume in biopharmaceutical company Immune
Response Corp. (NasdaqNM:IMNR - news) increased amid call activity after the stock set a
new 52-week high early Wednesday.
By 10:47 a.m. CST, about 1,072 calls and 72 put contracts had changed hands on the CBOE, compared with average daily volume
of 1,033 contracts.
Volume was also up on Tuesday with turnover of 2,554 contracts, consisting of 2,076 calls and 478 puts.
``They are selling the calls,`` said a Chicago Board Options Exchange trader who could point to no reason for the action.
The trader noted that implied volatility of the March 20 and 17.5 calls stayed high and stood at around 112 percent and 125
percent.
The busiest on the CBOE were the March 20 calls, which were off 7/8 to 1-1/8 on volume of 419 and open interest of 20.
March 20 puts did not trade and had no open interest.
The company said Wednesday that a Phase II trial of its immune-boosting drug Remune showed an increase in T-cell count in
HIV-infected subjects.
Shares of Immune Response dipped 3/16 to 17-1/2, off the new year`s high of 19-1/2, on Nasdaq volume of 2.3 million.
The stock has been trending higher for the past few days since closing at 10 on Feb. 15.
Wednesday February 23, 2:45 pm Eastern Time
U.S. Options - Immune Response volume increases
CHICAGO, Feb 23 (Reuters) - Options volume in biopharmaceutical company Immune
Response Corp. (NasdaqNM:IMNR - news) increased amid call activity after the stock set a
new 52-week high early Wednesday.
By 10:47 a.m. CST, about 1,072 calls and 72 put contracts had changed hands on the CBOE, compared with average daily volume
of 1,033 contracts.
Volume was also up on Tuesday with turnover of 2,554 contracts, consisting of 2,076 calls and 478 puts.
``They are selling the calls,`` said a Chicago Board Options Exchange trader who could point to no reason for the action.
The trader noted that implied volatility of the March 20 and 17.5 calls stayed high and stood at around 112 percent and 125
percent.
The busiest on the CBOE were the March 20 calls, which were off 7/8 to 1-1/8 on volume of 419 and open interest of 20.
March 20 puts did not trade and had no open interest.
The company said Wednesday that a Phase II trial of its immune-boosting drug Remune showed an increase in T-cell count in
HIV-infected subjects.
Shares of Immune Response dipped 3/16 to 17-1/2, off the new year`s high of 19-1/2, on Nasdaq volume of 2.3 million.
The stock has been trending higher for the past few days since closing at 10 on Feb. 15.
.
Hallo 109,
wirklich eine saublöde Art des Versuchs,
einen veralteten Thread wieder reinzustellen,
und das gleich zweimal.
Wenn Du auf deinen IMR sitzt, schreib doch wenigstens
wie die anderen Pusher "IMNR Kursziel 150 Euro" oder sowas.
Dr.Hook
wirklich eine saublöde Art des Versuchs,
einen veralteten Thread wieder reinzustellen,
und das gleich zweimal.
Wenn Du auf deinen IMR sitzt, schreib doch wenigstens
wie die anderen Pusher "IMNR Kursziel 150 Euro" oder sowas.
Dr.Hook
Hallo
Immune Responce steigt heute wieder einmal ziemlich rasant.
Gibt es da News?
Gruß
guntis
Immune Responce steigt heute wieder einmal ziemlich rasant.
Gibt es da News?
Gruß
guntis
Dr.Hook,
vielen Dank für die nette und höfliche Information.
vielen Dank für die nette und höfliche Information.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 155 | ||
| 133 | ||
| 108 | ||
| 59 | ||
| 56 | ||
| 49 | ||
| 47 | ||
| 47 | ||
| 40 | ||
| 35 |
| Wertpapier | Beiträge | |
|---|---|---|
| 31 | ||
| 30 | ||
| 29 | ||
| 28 | ||
| 28 | ||
| 23 | ||
| 21 | ||
| 19 | ||
| 18 | ||
| 17 |
